Neoadjuvant Treatment Study Using Targeted Therapies Based on Genetic Testing for Patients With Unresectable Stage III Non-Small Cell Lung Cancer Harboring Rare Mutations Excluding Common EGFR Mutations

What this Trial Is About

This research aims to evaluate targeted therapies guided by next generation sequencing NGS for patients with treatment-naive unresectable stage III non-small-cell lung cancer NSCLC whose tumors have rare mutations, excluding common EGFR sensitizing mutations. The study addresses challenges in treating this large and diverse patient group and explores surgery after targeted drug treatment for those with specific rare genetic changes. Participants receive one of several targeted drug treatments based on their tumors rare mutation type, including drugs like Sunvozertinib, Crizotinib, Pralsetinib, Larotrectinib, Savolitinib, Pyrotinib, Dabrafenib plus Trametinib, Glecirasib, or Ensartinib. Each treatment is given orally for three cycles, with each cycle lasting 28 days. Following these induction therapies, patients may undergo surgery. Throughout the study, participants will be monitored for the ability to undergo surgery within 6 months, side effects up to 24 months, disease-free survival, overall survival, and perioperative complications for up to 12 months. Blood and tissue samples will be collected before and after treatment. The study lasts several years, with follow-up assessments extending up to two years after the last patient is enrolled to evaluate treatment outcomes and safety.

Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.